Crinetics Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Checking your notes…
(in thousands, except per share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $114,341 | $101,536 |
| Investment securities, amortized cost of $1,178,076 at March 31, 2026 and $924,317 at December 31, 2025 | 1,176,965 | 926,353 |
| Trade accounts receivable, net | 5,683 | 592 |
| Inventory | 3,064 | 2,022 |
| Prepaid expenses and other current assets | 22,361 | 17,839 |
| Total current assets | 1,322,414 | 1,048,342 |
| Property and equipment, net | 13,497 | 14,296 |
| Operating lease right-of-use assets | 39,790 | 40,492 |
| Restricted cash, net of current portion | 800 | 800 |
| Prepaid expenses and other assets, net of current portion | 24,822 | 22,327 |
| TOTAL ASSETS | $1,401,323 | $1,126,257 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $37,487 | $41,770 |
| Accrued compensation and related expenses | 25,792 | 35,578 |
| Deferred revenue | 1,271 | 1,235 |
| Operating lease liabilities | 6,536 | 6,489 |
| Total current liabilities | 71,086 | 85,072 |
| Operating lease liabilities, non-current | 41,319 | 42,052 |
| Deferred revenue, non-current | 3,346 | 3,810 |
| Other liabilities | 4,926 | 3,240 |
| TOTAL LIABILITIES | 120,677 | 134,174 |
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 2025 | 2,828,204 | 2,407,757 |
| Accumulated other comprehensive (loss) income | (1,254) | 1,865 |
| Accumulated deficit | (1,545,272) | (1,417,427) |
| Stock held in trust | (1,032) | (112) |
| TOTAL STOCKHOLDERS’ EQUITY | 1,280,646 | 992,083 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $1,401,323 | $1,126,257 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.